[Effect of renokinase on the space velocity of coronary vein flow during systemic administration to patients with acute myocardial infarct].
A new thrombolytic drug, renokinase, was administered intravenously to 30 patients with macrofocal myocardial infarction (MI), admitted to hospital within early hours of its onset. Changes in the venous network of the heart were assessed, using continuous thermodilution, in the presence of thrombolytic treatment. Coronary venous flow was shown to increase by 20% and more in 17 patients, more than 30% in 15 patients, and more than 40% in 10. Low MI was associated with a significant increase of blood flow rate in the coronary sinus as well as other cardiac veins, while anterior MI was associated with flow rate increase in the coronary sinus only. A 20-30% increase in any of the coronary flow parameters limited the necrosis focus, as evidenced by precordial mapping from 35 ECG leads. Renokinase (60,000 units) was well tolerated by the patients.
Terekhov
V N
VN
Bogatyrev
I V
IV
Makolkin
V I
VI
Syrkin
A L
AL
Bokarev
I N
IN
D000328:Adult; D000368:Aged; D003326:Coronary Circulation / Q000187:drug effects*; D003331:Coronary Vessels; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage* / Q000627:therapeutic use
D014568:Urokinase-Type Plasminogen Activator
Vliianie renokinazy na ob"emnuiu skorost' koronarnogo venoznogo krovotoka pri sistemnom vvedenii bol'nym ostrym infarktom miokarda.